MedTrace Logo

Oral Dexmedetomidine in Pediatric MRI

NCT05619627 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-08

No results posted yet for this study

Summary

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.

Conditions

  • Anesthesia

Interventions

DRUG

Dexmedetomidine

Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI

DRUG

General Anesthesia (control group)

Participants will receive general anesthesia for their MRI

Sponsors & Collaborators

  • Soroush Merchant

    lead OTHER

Principal Investigators

  • Soroush Merchant, MD, MS · Children's Mercy Hospital Kansas City

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619627 on ClinicalTrials.gov